GAMs Transformation zeigt Wirkung: Verwaltetes Vermögen steigt dank starker Bruttoneugeldzuflüsse und verbesserter Anlageperformance, während Kundenabflüsse deutlich sinken

GAM reported an H1 2026 loss before tax improving 39% to CHF 24.7m (IFRS) and 30% to CHF 24.0m (adjusted), alongside a 17% decline in adjusted operating costs to CHF 47.8m. Assets under management rose to CHF 12.7bn (from CHF 12.5bn), with gross net new money of CHF 0.9bn and customer outflows down 81% to CHF 0.8bn, resulting in adjusted net inflows of CHF 38m (excluding a CHF 0.4bn segregated-account withdrawal tied to prior restructuring). Performance also strengthened, with 96% of Alternatives AUM beating 3-year benchmarks and 64% of total AUM beating 3-year benchmarks—supporting management’s view of a scalable, cost-disciplined turnaround.

Analysis

The investable read is not “GAM is fixed,” but “GAM is becoming a smaller-burn platform with one credible growth engine.” Alternatives and fixed income can now subsidize the rest of the franchise, yet the equity sleeve still looks like a drag on consultant acceptance, so the mix shift matters more than the headline AUM print. If institutional RFP momentum is real, the first beneficiaries are the highest-conviction, capacity-constrained strategies; the losers are larger multi-asset competitors that relied on GAM’s weakness to pick up mandates in alternatives and niche credit.

The key second-order issue is concentration: one client movement can still overwhelm underlying flow momentum, which means the market should discount any “positive net flows” claim until it is repeated for several quarters without balance-sheet noise. Cost cuts help the path to breakeven, but they do not solve the math unless organic inflows accelerate enough to lift fee-bearing AUM meaningfully; otherwise this remains a survivability story, not a compounding story. That makes the next 1-2 quarters the real catalyst window, while the 6-18 month risk is that the business reverts to a low-growth, low-multiple asset gatherer.

Contrarian view: consensus may be too focused on cost discipline and not enough on the quality of revenue. The improvement is concentrated in the areas that are easiest to market today, while the weakest segment still has limited evidence of durable institutional penetration. If the broader market tightens risk appetite, smaller alternatives boutiques and cat-bond/ILS managers could continue taking share from GAM rather than the other way around.

Key Decisions for Investors

• GMHLF: do not chase the print; wait 1-2 quarters for a second confirmation that adjusted net inflows stay positive ex one-offs. Falsifier: any renewed client withdrawal or higher Rock facility usage.
• GMHLF: if the shares sell off on skepticism but management reaffirms unchanged financing and AUM holds above CHF 13bn next update, consider a very small tactical long as a 6-12 month re-rating trade. Upside is survival-to-normalization; downside is dilution/default risk.
• Trim any existing GMHLF exposure into strength unless you have a high-conviction view on 2026-2027 product launches. This is a liquidity-sensitive turnaround, not a clean compounding story.
• Do not trade SSREY aggressively off this release; treat the ILS mention as a read-through to the asset class only. Reassess only if Swiss Re commentary later shows fee/share capture or reinsurance pricing spillover.